Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Freedman

Showing results (231-240 of 1,513) with videos related to

Pageof 152
Sort By:
Thorax|January 1, 1983
Production of lactic acid by respiratory musclesS Freedman, N T Cooke, J Moxham
The Journal of Pharmacy and Pharmacology|September 1, 1970
The inhibition of catecholamine biosynthesis by apomorphineM Goldstein, L S Freedman, T Backstrom
Radiology|September 1, 1972
A correction method for high-count-rate quantitative radionuclide angiographyG S Freedman, T Kinsella, A Dwyer
Statistics in Medicine|October 1, 1988
Comparing the effects of different durations of the same therapyL S Freedman, B L de Stavola
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 6, 2012
Mesenchymal stem cells as treatment for MS - progress to dateAntonio Uccelli, Alice Laroni, Mark S Freedman
The Journal of Biological Chemistry|May 25, 1991
Characterization of a GTPase-activating protein for the Ras-related Ral proteinR Emkey, S Freedman, L A Feig
Statistical Methods in Medical Research|December 17, 2013
Estimating and testing interactions when explanatory variables are subject to non-classical measurement errorHavi Murad, Victor Kipnis, Laurence S Freedman
Therapeutic Advances in Chronic Disease|January 16, 2016
Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseasesDaniele D'Ambrosio, Mark S Freedman, Joerg Prinz
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 21, 2015
Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to ManagementMoeber Mahzari, Amel Arnaout, Mark S Freedman
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 26, 2018
Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER studyMark S Freedman, Julia Morawski, Karthinathan Thangavelu
Pageof 152

Showing results (231-240 of 1,513) with videos related to

Sort By:
Pageof 152
Thorax|January 1, 1983
Production of lactic acid by respiratory musclesS Freedman, N T Cooke, J Moxham
The Journal of Pharmacy and Pharmacology|September 1, 1970
The inhibition of catecholamine biosynthesis by apomorphineM Goldstein, L S Freedman, T Backstrom
Radiology|September 1, 1972
A correction method for high-count-rate quantitative radionuclide angiographyG S Freedman, T Kinsella, A Dwyer
Statistics in Medicine|October 1, 1988
Comparing the effects of different durations of the same therapyL S Freedman, B L de Stavola
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 6, 2012
Mesenchymal stem cells as treatment for MS - progress to dateAntonio Uccelli, Alice Laroni, Mark S Freedman
The Journal of Biological Chemistry|May 25, 1991
Characterization of a GTPase-activating protein for the Ras-related Ral proteinR Emkey, S Freedman, L A Feig
Statistical Methods in Medical Research|December 17, 2013
Estimating and testing interactions when explanatory variables are subject to non-classical measurement errorHavi Murad, Victor Kipnis, Laurence S Freedman
Therapeutic Advances in Chronic Disease|January 16, 2016
Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseasesDaniele D'Ambrosio, Mark S Freedman, Joerg Prinz
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 21, 2015
Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to ManagementMoeber Mahzari, Amel Arnaout, Mark S Freedman
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 26, 2018
Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER studyMark S Freedman, Julia Morawski, Karthinathan Thangavelu
Pageof 152